WallStreetZenWallStreetZen

NASDAQ: CGEM
Cullinan Oncology Inc Stock Forecast, Predictions & Price Target

Analyst price target for CGEM

Based on 2 analysts offering 12 month price targets for Cullinan Oncology Inc.
Min Forecast
$22.00+171.27%
Avg Forecast
$28.00+245.25%
Max Forecast
$34.00+319.24%

Should I buy or sell CGEM stock?

Based on 2 analysts offering ratings for Cullinan Oncology Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CGEM stock forecasts and price targets.

CGEM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-10-06
lockedlocked$00.00+00.00%2023-08-11

1 of 1

Forecast return on equity

Is CGEM forecast to generate an efficient return?
Company
N/A
Industry
-0.69%
Market
30.34%

Forecast return on assets

Is CGEM forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.29%

CGEM revenue forecast

What is CGEM's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$10.8M
Avg 2 year Forecast
$44.8M
Avg 3 year Forecast
$51.9M

CGEM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CGEM$8.11$28.00+245.25%Strong Buy
ABUS$2.07$6.00+189.86%Strong Buy
ALT$6.48$12.67+95.48%Strong Buy
GRCL$5.14$15.00+191.83%Strong Buy
GNLX$12.84$35.00+172.59%Strong Buy

Cullinan Oncology Stock Forecast FAQ

Is Cullinan Oncology Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CGEM) stock is to Strong Buy CGEM stock.

Out of 2 analysts, 1 (50%) are recommending CGEM as a Strong Buy, 1 (50%) are recommending CGEM as a Buy, 0 (0%) are recommending CGEM as a Hold, 0 (0%) are recommending CGEM as a Sell, and 0 (0%) are recommending CGEM as a Strong Sell.

If you're new to stock investing, here's how to buy Cullinan Oncology stock.

What is CGEM's revenue growth forecast for 2024-2026?

(NASDAQ: CGEM) Cullinan Oncology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.

Cullinan Oncology's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast CGEM's revenue for 2024 to be $463,571,058, with the lowest CGEM revenue forecast at $463,571,058, and the highest CGEM revenue forecast at $463,571,058. On average, 2 Wall Street analysts forecast CGEM's revenue for 2025 to be $1,916,786,754, with the lowest CGEM revenue forecast at $1,792,551,764, and the highest CGEM revenue forecast at $2,041,064,525.

In 2026, CGEM is forecast to generate $2,220,315,424 in revenue, with the lowest revenue forecast at $2,220,315,424 and the highest revenue forecast at $2,220,315,424.

What is CGEM's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: CGEM) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.29%.

What is CGEM's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CGEM price target, the average CGEM price target is $28.00, with the highest CGEM stock price forecast at $34.00 and the lowest CGEM stock price forecast at $22.00.

On average, Wall Street analysts predict that Cullinan Oncology's share price could reach $28.00 by Oct 6, 2024. The average Cullinan Oncology stock price prediction forecasts a potential upside of 245.25% from the current CGEM share price of $8.11.

What is CGEM's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: CGEM) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.